Palliative interventions in patients with peritoneal metastases and malignant bowel obstruction

Journal of Clinical Oncology

Volumn 30, Issue 35, 2012, Pages 4290-4291

  Bellavance, Emily C ^a   Alexander, H Richard ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN;

EDITORIAL; HUMAN; INTESTINE OBSTRUCTION; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PERITONEUM METASTASIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

EID: 84870739713     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.0536     Document Type: Editorial

References (13)

1. Ripamonti C, Twycross R, Baines M, et al: Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer 9:223-233, 2001 (Pubitemid 32537280)
2. Matulonis UA, Seiden MV, Roche M, et al: Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer. J Pain Symptom Manage 30:563-569, 2005 (Pubitemid 41821208)
3. Hisanaga T, Shinjo T, Morita T, et al: Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction. Jpn J Clin Oncol 40:739-745, 2010
4. Baines M, Oliver DJ, Carter RL: Medical management of intestinal obstruction in patients with advanced malignant disease: A clinical and pathological study. Lancet 2:990-993, 1985 (Pubitemid 16215450)
5. Laval G, Rousselot H, Toussaint-Martel S, et al: SALTO: A randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction. Bull Cancer 99:E1-E9, 2012
6. Mercadante S, Ripamonti C, Casuccio A, et al: Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer 8:188-191, 2000 (Pubitemid 30183034)
7. Mystakidou K, Tsilika E, Kalaidopoulou O, et al: Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: A randomized, doubleblind, controlled clinical trial. Anticancer Res 22:1187-1192, 2002 (Pubitemid 34836172)
8. Ripamonti C, Mercadante S, Groff L, et al: Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: A prospective randomized trial. J Pain Symptom Manage 19:23-34, 2000 (Pubitemid 30067620)
9. Watari H, Hosaka M, Wakui Y, et al: A prospective study on the efficacy of octreotide in the management of malignant bowel obstruction in gynecologic cancer. Int J Gynecol Cancer 22:692-696, 2012
10. Mariani P, Blumberg J, Landau A: Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction due to peritoneal carcinomatosis: A randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 30:4337-4343, 2012
11. Rinck GC, van den Bos GA, Kleijnen J, et al: Methodologic issues in effectiveness research on palliative cancer care: A systematic review. J Clin Oncol 15:1697-1707, 1997 (Pubitemid 27167411)
12. Shelby-James TM, Hardy J, Agar M, et al: Designing and conducting randomized controlled trials in palliative care: A summary of discussions from the 2010 clinical research forum of the Australian Palliative Care Clinical Studies Collaborative. Palliat Med [epub ahead of print on August 15, 2011]
13. Laneader A, Angelos P, Ferrell BR, et al: Ethical issues in research to improve the management of malignant bowel obstruction: Challenges and recommendations. J Pain Symptom Manage 34:S20-S27, 2007 (Pubitemid 46970814)